AU2011322597B2 - Dosing regimes for the treatment of ocular vascular disease - Google Patents

Dosing regimes for the treatment of ocular vascular disease Download PDF

Info

Publication number
AU2011322597B2
AU2011322597B2 AU2011322597A AU2011322597A AU2011322597B2 AU 2011322597 B2 AU2011322597 B2 AU 2011322597B2 AU 2011322597 A AU2011322597 A AU 2011322597A AU 2011322597 A AU2011322597 A AU 2011322597A AU 2011322597 B2 AU2011322597 B2 AU 2011322597B2
Authority
AU
Australia
Prior art keywords
vegf
yloxy
amide
pyrimidin
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2011322597A
Other languages
English (en)
Other versions
AU2011322597A1 (en
Inventor
Mitchell Brigell
Peter End
Vinayak Hosagrahara
Bruce Jaffee
Erik Meredith
Ronald Newton
Stephen Poor
Yubin Qiu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2011322597A1 publication Critical patent/AU2011322597A1/en
Application granted granted Critical
Publication of AU2011322597B2 publication Critical patent/AU2011322597B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2011322597A 2010-10-27 2011-10-25 Dosing regimes for the treatment of ocular vascular disease Ceased AU2011322597B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40721810P 2010-10-27 2010-10-27
US61/407,218 2010-10-27
PCT/EP2011/068682 WO2012055884A1 (en) 2010-10-27 2011-10-25 Dosing regimes for the treatment of ocular vascular disease

Publications (2)

Publication Number Publication Date
AU2011322597A1 AU2011322597A1 (en) 2013-05-02
AU2011322597B2 true AU2011322597B2 (en) 2015-09-10

Family

ID=44913251

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011322597A Ceased AU2011322597B2 (en) 2010-10-27 2011-10-25 Dosing regimes for the treatment of ocular vascular disease

Country Status (12)

Country Link
US (1) US20130197016A1 (enExample)
EP (1) EP2632458B1 (enExample)
JP (1) JP5934229B2 (enExample)
KR (1) KR20140008303A (enExample)
CN (1) CN103167873A (enExample)
AU (1) AU2011322597B2 (enExample)
BR (1) BR112013009701A2 (enExample)
CA (1) CA2814439A1 (enExample)
EA (1) EA022873B1 (enExample)
ES (1) ES2547145T3 (enExample)
MX (1) MX2013004782A (enExample)
WO (1) WO2012055884A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9395468B2 (en) 2012-08-27 2016-07-19 Ocular Dynamics, Llc Contact lens with a hydrophilic layer
US9353122B2 (en) * 2013-02-15 2016-05-31 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US10174006B2 (en) 2013-06-06 2019-01-08 Novartis Ag Topical aqueous ophthalmic compositions containing a 1H-indole-1-carboxamide derivative and use thereof for treatment of ophthalmic disease
EP3570093B1 (en) 2013-11-15 2021-09-15 Tangible Science, Inc. Contact lens with a hydrophilic layer
JPWO2015147204A1 (ja) * 2014-03-27 2017-04-13 国立大学法人京都大学 血管新生増殖因子を阻害する医薬組成物
CN107206119B (zh) 2014-12-09 2021-01-29 实体科学公司 具有生物相容性层的医疗设备涂层
PE20240329A1 (es) 2019-06-05 2024-02-27 Regeneron Pharma Dispositivos y metodos para administracion de dosis de precision
WO2021067823A2 (en) * 2019-10-05 2021-04-08 The Schepens Eye Research Institute, Inc. A new treatment for meibomian gland dysfunction
US12649031B2 (en) 2021-09-08 2026-06-09 Regeneron Pharmaceuticals, Inc. Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100111963A1 (en) * 2006-11-10 2010-05-06 Genentech, Inc. Method for treating age-related macular degeneration
WO2010066684A2 (en) * 2008-12-09 2010-06-17 Novartis Ag Pyridyloxyindoles Inhibitors of VEGF-R2 and Use Thereof for Treatment of Disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1382604B1 (en) 2001-04-27 2005-12-28 Kirin Beer Kabushiki Kaisha Quinoline derivative having azolyl group and quinazoline derivative
PE20060664A1 (es) 2004-09-15 2006-08-04 Novartis Ag Amidas biciclicas como inhibidores de cinasa
EP2380572A1 (en) 2005-11-29 2011-10-26 Glaxosmithkline LLC Cancer treatment method

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100111963A1 (en) * 2006-11-10 2010-05-06 Genentech, Inc. Method for treating age-related macular degeneration
WO2010066684A2 (en) * 2008-12-09 2010-06-17 Novartis Ag Pyridyloxyindoles Inhibitors of VEGF-R2 and Use Thereof for Treatment of Disease

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BASHSHUR ZF, et al. Am J Ophthalol, (2006) Vol 142, pp 1-9. *
CHUNG EJ, et al. Br J Ophthalmol, (2009), Vol 93, pp 958-963. *
KOURLAS H, et al. Clinical Therapeutics, (2006) Vol 28 No 1, pp 36-44. *
NICHOLSON BP, et al. Graefes Arch Clin Exp Ophthalmol, (2010), Vol 248, pp 915-930. *
TAKAHASHI K, et al. Arch Opthalmol, (2009) Vol 127(4), pp 494-499. *
WIEGAND SJ, et al. Invest Ophthalmol Vis Sci, (2005) Vol 46: E-Abstract 1411. *

Also Published As

Publication number Publication date
BR112013009701A2 (pt) 2016-07-19
EP2632458A1 (en) 2013-09-04
JP2013540791A (ja) 2013-11-07
US20130197016A1 (en) 2013-08-01
JP5934229B2 (ja) 2016-06-15
AU2011322597A1 (en) 2013-05-02
EA022873B1 (ru) 2016-03-31
EP2632458B1 (en) 2015-08-12
MX2013004782A (es) 2013-06-03
WO2012055884A1 (en) 2012-05-03
CN103167873A (zh) 2013-06-19
ES2547145T3 (es) 2015-10-02
KR20140008303A (ko) 2014-01-21
CA2814439A1 (en) 2012-05-03
EA201390618A1 (ru) 2013-08-30

Similar Documents

Publication Publication Date Title
EP2632458B1 (en) Dosing regimes for the treatment of ocular vascular disease
CN108135737B (zh) 用于治疗翼状胬肉的组合物和方法
AU2019226212B2 (en) Combination of Pl3K inhibitor and c-Met inhibitor
US20130012531A1 (en) Treatment method
TW200815416A (en) Compositions and methods for treating, reducing, ameliorating, or alleviating posterior-segment ophthalmic diseases
JP5049139B2 (ja) 内臓痛を治療するためのオキシコドンの使用
EP2671589A1 (en) Medicinal agent for prevention or treatment of diseases associated with intraocular neovascularization and/or intraocular vascular hyperpermeability
CN106376232B (zh) 用于持续释放癸二酰二纳布啡酯的药物制剂
JP2023099169A (ja) 多標的阻害剤の医薬
AU2014274955B2 (en) Topical aqueous ophthalmic compositions containing a 1H-indole-1-carboxamide derivative and use thereof for treatment of ophthalmic disease
CN101500567B (zh) P38激酶抑制剂治疗精神障碍的用途
US20080234285A1 (en) Combination of Organic Compounds
HK40069641A (en) Compositions and methods for treating pterygium
HK1230095A1 (en) Pharmaceutical formulations for sustained release of sebacoyl dinalbuphine ester
HK1256602B (en) Compositions and methods for treating pterygium

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired